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Abstract. Fibroblast growth factor 15 (FGF15) was previously 
identified to be highly expressed in the ileum and functions as 
an endocrine factor to regulate bile acid synthesis in the liver. 
FGF15 targets its receptor fibroblast growth factor receptor 
4 in the liver and serves important roles in energy metabo-
lism, including bile acid homeostasis, glucose metabolism 
and protein synthesis. The expression of FGF15 is known to 
be regulated by the transcription factor farnesoid X receptor 
(FXR). In the present study, reverse transcription-quantitative 
polymerase chain reaction was used for measuring Fgf15 
expression from the animal and tissue culture experiments, 
and it was identified that dexamethasone, a drug widely used in 
anti‑inflammation therapy, and a classical inducer of glucocor-
ticoid receptor (GR)- and pregnane X receptor (PXR)-target 
genes, may downregulate Fgf15 expression in the ileum. GR 
was identified to be highly expressed in the ileum by western 
blot analysis. Furthermore, it was demonstrated that the down-
regulation of Fgf15 by dexamethasone is due to the repression 
of ileal FXR activity via GR; however, not PXR, in the ileum. 
The present results provide insight for a better understanding 
of the adverse effects associated with dexamethasone therapy.
Introduction
Fibroblast growth factor 15 (FGF15) was initially identified in 
the developing nervous system of a mouse (1). Subsequently, 
the human ortholog, fibroblast growth factor 19 (FGF19), was 
identified to be expressed in the fetal brain (2). Previous studies 
suggested that FGF15 functioned in cell division and patterning 
within specific regions of the embryonic brain, spinal cord and 
sensory organs (1,2). Other previous studies demonstrated that 
FGF15/19 exhibited high expression in the small intestine of 
adult mice and humans, where they function as an entero-
hepatic signal to regulate hepatic homeostasis (3,4). Further 
studies demonstrated that circulating FGF15/19 as metabolic 
hormones functioned through fibroblast growth factor receptor 
4 (FGFR4) in the liver and regulated numerous metabolism 
pathways, including hepatic bile acid (BA), carbohydrate and 
protein metabolism (3-7).
FGF15 expression is regulated by farnesoid X receptor 
(FXR), a BA receptor (3). Retinoid X receptors (RXRs) are 
hypothesized to form a heterodimer with FXR and serve a 
role in the transcriptional regulation of Fgf15 (3). Vitamin D 
may additionally activate the transcription of Fgf15 through 
vitamin D receptor (8), whereas, vitamin A upregulates Fgf15 
expression through the RXR/FXR heterodimer (8). Notably, 
Diet1 was demonstrated to promote FGF15 production at 
the post-transcriptional level, and an absence of Diet1 was 
accompanied by significantly reduced FGF15 secretion (9). 
These results demonstrate the present understanding of Fgf15 
regulation. Whether other transcription factors are involved in 
the regulation of Fgf15 expression is unclear.
Dexamethasone (Dex), a synthetic analog of gluco-
corticoids (GCs), is a potent agonist for the glucocorticoid 
receptor (GR). Due to its function of anti‑inflammation, Dex 
has been widely used in the treatment of acute inflammatory 
and autoimmune diseases (10). Unfortunately, accumulating 
evidence demonstrated that the clinical use of GCs or Dex 
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causes a lot of undesirable side effects (11,12). For example, 
GC intake may result in glucose intolerance and insulin 
resistance (11). Increased GCs may cause liver steatosis and 
hyperlipidemia (12). Treatment with GCs additionally leads 
to BA overproduction and gallstone disease (13). As FGF15 
serves an important role in glucose metabolism, insulin resis-
tance and BA synthesis (3,14), the effects of Dex on Fgf15 
expression were hypothesized to affect the homeostasis of BA 
and glucose, and may lead to the adverse effects associated 
with treatments with GCs in the clinical setting. The present 
study aimed to investigate the effect of Dex on the expression 
of Fgf15 in the mouse ileum. It was identified that treatment 
with Dex significantly downregulated ileal Fgf15 expression, 
and this downregulation of Fgf15 expression by Dex is due to 
GR‑mediated suppression of FXR transcriptional activity.
Materials and methods
Materials. Cholic acid (CA), pregnenolone-16-α-carbonitrile 
(PCN) and Dex were purchased from Sigma‑Aldrich (Merck 
KGaA, Darmstadt, Germany). An anti‑GR antibody was 
purchased from Epitomics (Abcam, Cambridge, UK) and 
an anti‑GAPDH antibody was purchased from GenScript 
(Piscataway, NJ, USA).
Animals and treatments. All animal studies were approved 
by the Institutional Animal Care and Use Committee of the 
Wadsworth Center (State University of New York, Albany, 
NY, USA) or the Animal Ethics Committee of the Fujian 
Agriculture and Forestry University (Fuzhou, China). In total, 
120 adult male C56BL/6J mice (~25 g; 2‑3 months old, 3 mice 
per group; breeding and feeding in the laboratory) were used 
for all experiments. Animals were maintained at 22˚C, 50% 
relative humidity and a 12‑h light/dark cycle in a specific 
pathogen‑free clean room with food and water ad libitum. Dex 
dissolved in corn oil was administered to the mice at various 
doses via intraperitoneal (i.p.) injection. For dose-response 
experiments, mice were treated with Dex at three different 
doses (0.8, 8 and 80 mg/kg) for 24 h. Animals were sacrificed 
at the indicated timepoints following treatment with Dex for 
tissue collection. Additionally, the weights of the mice and 
tissue, and tissue morphology were examined to evaluate the 
toxicity of treatment with Dex. PCN (25 mg/kg, dissolved 
in corn oil) was administered via oral gavage, and mice 
were sacrificed at 24 h after treatment with PCN for tissue 
Collection.
For the co‑treatment of CA and Dex, Dex at 80 mg/kg 
or vehicle (corn oil) was administered by i.p. injection. Mice 
fasted for 2 h prior to administration of CA (200 mg/kg in PBS 
by oral gavage). After another 4 h, ileal epithelial cells were 
collected for RNA preparation.
Sample collection and western blot analysis. The small 
intestine was removed and flushed with ice cold PBS. The 
small intestine was divided into three segments designated 
the duodenum (proximal 5 cm), jejunum (middle 5 cm) 
and ileum (distal 5 cm). The three segments were cut open 
longitudinally and the epithelial cells were removed by gentle 
scraping. The collected cells were washed once in cold PBS 
and subsequently lysed in radioimmunoprecipitation assay 
buffer (Thermo Fisher Scientific, Inc., Waltham, MA, USA) 
containing Protease & Phosphatase Inhibitor (Thermo Fisher 
Scientific, Inc.) and 5 mM EDTA, and homogenized using 
a polytron homogenizer. The homogenates were mixed for 
10 min at 4˚C, and subsequently centrifuged at 14,000 g and 
4˚C for 15 min. The supernatant was collected and the protein 
concentration was determined by the bicinchoninic acid 
method (Pierce; Thermo Fisher Scientific, Inc.).
Proteins (50 µg) were resolved on 10% NuPAGE 
Bis‑Tris‑gels (Invitrogen; Thermo Fisher Scientific, Inc.) and 
subsequently transferred to nitrocellulose membranes. For 
immunodetection, subsequent to blocking with 5% fat‑free 
milk at room temperature for 1 h, pre‑cut membranes were 
incubated with monoclonal rabbit anti‑GR (Epitomics; Abcam; 
cat. no. EPR4595; 1:4,000) and goat anti-GAPDH (GenScript; 
cat. no. A00191‑40; 1:40,000) antibodies at 4˚C overnight. 
Subsequent to washing, the membranes were incubated with 
goat anti‑rabbit immunoglobulin G (IgG) heavy and light 
chain (H&L) horseradish peroxidase (HRP)‑conjugated 
antibod (GenScript; cat. no. A00098; 1:8,000) or donkey 
anti-goat IgG H&L HRP-conjugated antibody (GenScript; 
cat. no. A00178; 1:8,000) according to the host species of 
the primary antibody at room temperature for 1 h. Pierce™ 
Enhanced Chemiluminescent Western Blotting Substrate 
(Thermo Fisher Scientific, Inc.) was used for the detection 
of HRP on the immunoblots. Immunoblot quantification 
was performed using a Bio‑Rad ChemiDoc XRS+ System 
(Bio‑Rad Laboratories, Inc., Hercules, CA, USA) with Image 
Lab 3.0 (Bio-Rad Laboratories, Inc.).
Ex vivo culture of ileum tissues. Immediately after harvesting 
the intestine, 5 cm of the terminal ileum was flushed with PBS 
to remove the contents and was subsequently cut into small 
segments (1x3 mm). The segments were cultured at 37˚C for 
4 h in Dulbecco's modified Eagle's medium (Thermo Fisher 
Scientific, Inc.) supplemented with 10% heat‑inactivated fetal 
bovine serum (Thermo Fisher Scientific, Inc.), 100 units/ml 
penicillin and 100 µg/ml streptomycin. Dex (1 µM final concen-
tration) or vehicle (ethanol), and CA (100 µg/ml) or PBS 
were added to the culture medium. The epithelial cells were 
collected at the end of 4-h culture for RNA preparation.
RNA isolation and reverse transcription‑quantitative poly‑
merase chain reaction (RT‑qPCR) analysis. Total RNA was 
prepared from the enterocytes of individual mice, with the 
use of TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, 
Inc.), as previously described (15). RNA concentration 
and purity were determined spectrally, and the integrity 
of the RNA samples was assessed by ethidium bromide 
staining following agarose gel electrophoresis. RT-PCR 
was performed using 3 µg total RNA and SYBR Green 
PCR Master PCR Mix (Applied Biosystems; Thermo Fisher 
Scientific, Inc.), as previously described (16). The compara-
tive 2-∆∆Cq method was used for quantifying the relative 
mRNA expression levels (17,18). PCR primers for FXR (19), 
PXR (20), Fgf15 (3), small heterodimer partner (SHP) (3), 
glucocorticoid-induced leucine zipper (GILZ) (21), apical 
sodium dependent bile acid transporter (ASBT) (22), ileum 
bile acid binding protein (IBABP) (22) and cytochrome 
P450, family 3, subfamily a, polypeptide 11 Cyp3a11 (23) 
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were as follows: FXR, 5'-CCA ACC TGG GTT TCT ACC C-3' 
(forward) and 5'-CAC ACA GCT CAT CCC CTT T-3' (reverse); 
PXR, 5'-CAA GGC CAA TGG CTA CCA-3' (forward) and 
5'-CGG GTG ATC TCG CAG GTT-3' (reverse); Fgf15, 5'-GAG 
GAC CAA AAC GAA CGA AAT T-3' (forward) and 5'-ACG 
TCC TTG ATG GCA ATC G-3' (reverse); SHP, 5'-CGA TCC 
TCT TCA ACC CAG ATG-3' (forward) and 5'-AGG GCT CCA 
AGA CTT CAC ACA-3' (reverse); GILZ, 5'-CAG CAG CCA 
CTC AAA CCA GC-3' (forward) and; 5'-ACC ACA TCC CCT 
CCA AGC AG-3' (reverse); ASBT, 5'-TGG GTT TCT TCC 
TGG CTA GAC T-3' (forward) and 5'-TGT TCT GCA TTC 
CAG TTT CCA A-3' (reverse); IBABP, 5'-AGA TCA TCA CAG 
AGG TCC AGC-3' (forward) and 5'-GGT AGC CTT GAA CTT 
CTT GCC-3' (reverse); Cyp3a11, 5'-GAC AAA CAA GCA 
GGG ATG G-3' (forward) and 5'-AAT GTG GGG GAC AGC 
AAA G-3' (reverse); and U36B4, 5'-CGT CCT CGT TGG AGT 
GAC A-3' (forward) and 5'-CGGTGCGTCAGGGATTG-3' 
(reverse). The levels of the target mRNAs in various total 
RNA preparations were normalized by the level of U36B4 
mRNA (8).
Statistical analysis. All experiments were repeated at least 
three times. Data are presented as the mean ± standard devia-
tion. Statistical analysis was performed using Student's t‑test 
with SPSS 11.5 software (SPSS, Inc., Chicago, IL, USA). For 
multiple comparisons, one‑way analysis of variance followed 
by Fisher's Least Significant Difference test was used. P<0.05 
was considered to indicate a statistically significant difference.
Results
Treatment with Dex significantly downregulates Fgf15 
expression in the mouse ileum. To examine the effect of 
treatment with Dex on ileal Fgf15 expression, the mRNA 
expression levels of Fgf15 were compared prior to and 
following treatment with Dex. Mice were treated with Dex 
at three different doses (0.8, 8 and 80 mg/kg) for 24 h. 
The ileal Fgf15 expression decreased in a dose‑dependent 
manner following treatment with Dex (Fig. 1A). At 80 mg/kg 
Dex, the expression level of FGF15 mRNA was decreased 
to an undetectable level two days later (Fig. 1B). The down-
regulation of ileal Fgf15 expression by treatment with Dex 
was maintained when the mice were treated with Dex for 3 
consecutive days (Fig. 1B). These results suggested that treat-
ment with Dex was able to suppress ileal Fgf15 expression at 
the RNA level. At the same time, although the highest dosage 
of Dex used, 80 mg/kg, in the present study was effective, 
the potential cytotoxicity of Dex with this dosage for 3 days 
requires consideration (data not shown). The phenomenon 
of tissue hypertrophy was observed (data not shown), which 
may be due to the compensation for the cytotoxicity of treat-
ment with Dex with high dosage for 3 days.
Figure 1. Effect on FGF15 expression in mouse ileum. (A) Expression levels of ileal FGF15 mRNA were decreased in a dose‑dependent manner by treatment 
with Dex for 24 h. (B) Expression of FGF15 mRNA was completely suppressed following consecutive treatment with 80 mg/kg Dex for 1‑3 days. **P<0.01 vs. 
vehicle. (C) Dex diminished the induction of FGF15 by CA (200 mg/kg) in vivo. (D) Dex diminished the induction of FGF15 by treatment with CA (100 µg/ml) 
in the ileum culture ex vivo. The data were normalized to the expression levels of mouse U36B4. The data are presented as the mean ± standard deviation. n=3. 
*P<0.05, ***P<0.001. FGF15, fibroblast growth factor 15; Dex, dexamethasone; CA, cholic acid; N.D., not detectable.
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To investigate whether this downregulation of Fgf15 expres-
sion is mediated by FXR, the critical transcriptional factor for 
regulating Fgf15 expression (3), the effect of treatment with 
Dex on the FXR transcriptional activity was examined in vivo. 
Mice were pre‑treated with Dex or corn oil, and subsequently 
FXR was activated with CA. After a 4 h treatment with CA, 
as presented in Fig. 1C, the mRNA expression level of Fgf15 
was upregulated. However, the upregulation of Fgf15 expres-
sion by treatment with CA was significantly inhibited in mice 
pre‑treated with Dex (Fig. 1C; P<0.001), suggesting that Dex 
may interfere with FXR activation. Whether this suppres-
sion of Fgf15 expression by Dex directly occurred in ileal 
enterocytes, using an ex vivo culture system, was further inves-
tigated. As presented in Fig. 1D, CA induced Fgf15 expression 
in the ex vivo culture system, whereas, Dex interfered with the 
CA-induced FGF15 upregulation in ileal cells.
GR is expressed in the intestine and is able to respond to 
activation by Dex. GR may be activated by Dex, to trigger 
the transactivation or transrepression of GC-responsive 
genes (24-26). Therefore, GR protein expression levels in the 
small intestine were examined by western blot analysis. As 
presented in Fig. 2A, GR (~86 kDa) was expressed throughout 
the entire small intestine, between the duodenum and the 
ileum. Notably, GR expression in the small intestine exhibited 
a gradual increase between the duodenum and the ileum. The 
expression level of GR in ileum was ~3‑times higher compared 
with the duodenum and ~2‑times higher compared with the 
jejunum (Fig. 2B), suggesting that GR may have an impor-
tant function in the ileum. Subsequently, it was determined 
whether ileal GR may be activated by treatment with Dex at 
a concentration of 80 mg/kg. It was identified that the mRNA 
expression levels of two selected GR target genes, GILZ 
and ASBT (27-29), were upregulated by ~6 and ~2.5‑times, 
respectively, in the ileum following treatment with Dex for 
24 h (Fig. 2C). These results demonstrated that GR was highly 
expressed in the ileum and may be activated by Dex, and thus 
may potentially mediate the repression of Fgf15 expression by 
Dex.
Suppression of Fgf15 expression by Dex is not associated with 
PXR. As Dex is able to activate GR and PXR, it was further 
examined if the effect of Dex on FGF15 expression is medi-
ated by PXR. As presented in Fig. 3A, the suppression of Fgf15 
expression was observed following treatment with Dex. Since 
Fgf15 is the downstream gene for FXR activation, the expres-
sion of SHP and IBABP, another two classical FXR target 
genes (3,30,31), was further examined in the ileum following 
Figure 2. Expression of GR and GR target genes in the ileum. (A) Western blot analysis of GR protein expression in the small intestine. The entire small 
intestine was equally divided into three segments, representing the duodenum, jejunum and ileum. Proteins (50 µg each) were analyzed on western blots 
with antibodies against GR and GAPDH. (B) Quantification of GR protein expression from three independent experiments. The data were normalized to the 
expression levels of mouse GAPDH. (C) Upregulation of GR target genes (GILZ and ASBT) expression following treatment with Dex for 24 h. The data were 
normalized to the expression levels of mouse U36b4. The data are presented as the mean ± standard deviation. n=3. **P<0.01, ***P<0.001. GR, glucocorticoid 
receptor; GILZ, glucocorticoid‑induced leucine zipper; ASBT, apical sodium dependent bile acid transporter; Dex, dexamethasone.
MOLECULAR MEDICINE REPORTS  19:  2953-2959,  2019 2957
treatment with Dex. As expected, SHP and IBABP expres-
sion were additionally significantly downregulated following 
treatment with Dex (Fig. 3A; P<0.01). This downregulation of 
Fgf15, SHP and IBABP gene expression reflects the inhibition 
of FXR activity; however, not FXR expression, as there was no 
significant difference in FXR expression.
In addition to activating GR, Dex may additionally activate 
PXR to induce CYP3A expression (32,33). As presented in 
Fig. 3A, the expression of Cyp3a11, the target gene of PXR, 
was significantly increased in the ileum following treatment 
with Dex; however, there was no alteration in PXR expres-
sion, a result suggesting that the increased CYP3A expression 
was due to increased PXR activation. To confirm whether 
the suppression of Fgf15 expression by Dex is mediated by 
PXR activation, PCN, a typical PXR agonist, was used to 
treat mice in the same way as Dex. As presented in Fig. 3B, 
PCN induced the expression of Cyp3a11, a PXR target gene; 
however, it had no effect on the expression of either FXR or 
PXR, or FXR target genes, Fgf15 and IBABP, in the ileum. 
This result suggested that PXR activation did not contribute to 
the suppression of FGF15 expression by treatment with Dex.
Discussion
The present study demonstrated that treatment with Dex 
significantly suppressed the expression of Fgf15 in the mouse 
ileum. Although the concentration of serum FGF15 protein 
was not determined, the mRNA expression levels of Fgf15 are 
routinely used to represent the Fgf15 expression levels (3,4). 
Furthermore, as the Fgf15 mRNA expression levels were 
below the detectable level for at least 3 days during treat-
ment with Dex, this suggested that the protein expression 
level of FGF15 was additionally reduced by treatment with 
Dex. As previously demonstrated, FGF15/FGF19 serves an 
important role in BA homeostasis, glucose metabolism and 
hepatic protein synthesis (3,4,6). For example, Inagaki et al (3) 
identified that FGF15 inhibited BA synthesis by repressing 
associated gene expression in the liver (3). Potthoff et al (4) 
demonstrated that FGF15 inhibited hepatic gluconeogenesis 
by blocking the expression of genes involved in gluconeogen-
esis (4). Therefore, Dex intake has the potential to increase 
the risks of metabolic disorder by repressing Fgf15 expression. 
Of note, GCs or their synthetic analogs (including Dex) have 
been demonstrated to cause metabolic diseases, including 
hyperglycemia and liver steatosis in specific patients (11-13). 
Notably, the effects of Dex on Fgf15 expression were dose 
dependent. Therefore, an initial high dosage is occasionally 
recommended in the clinical setting; however, the consecutive 
use of Dex at high dosage is not recommended. Although the 
most effective dose of Dex (80 mg/kg) was studied, is higher 
compared with therapeutic doses, which may be as high as 
~6 mg/kg in emergency treatment, according to the US Food 
and Drug Administration approved drug dosage information 
for Dex (34), used in patients, a trend of inhibition was addi-
tionally observed at the lower, therapeutic, doses. Therefore, 
the underlying risks require consideration.
The present study further demonstrated that the down-
regulation of Fgf15 by Dex is associated with decreased 
transcriptional activity of FXR. As previously demonstrated, 
FXR, which may be activated by BAs, is considered the prin-
cipal transcriptional factor regulating Fgf15 expression (3). 
Therefore, the decrease in Fgf15 expression reflected the 
repression of FXR activity. The inhibition of FXR activity 
was further demonstrated by the result that treatment with 
Dex additionally suppressed the expression of SHP and 
IBABP, another two classical target genes of FXR in the 
ileum (3,30,31). Notably, the suppression of Fgf15 and IBABP 
by Dex was restricted to the ileum, as Fgf15 and IBABP are 
primarily expressed in the ileum (3,30). However, the inhibi-
tion of FXR activity by Dex may be not restricted to the ileum 
based on the preliminary observations of the present study. 
Considering that FXR and GR additionally coexist in other 
segments of small intestine (3), this hypothesis is reasonable. 
This suppression of FXR target gene expression by Dex was 
not accompanied by an alteration in the FXR expression level, 
which suggested that Dex did not regulate Fgf15 expression 
via suppression of FXR expression. However, how Dex inter-
feres with FXR activation remains unclear.
Figure 3. Suppression of FGF15 expression by Dex is potentially mediated by GR activation in the ileum. (A) GR activation by Dex (80 mg/kg) for 24 h 
induced CYP3A11 expression and suppressed the expression of FXR target genes (SHP, FGF15 and IBABP); however, did not affect FXR expression in 
the ileum. (B) PXR activation by PCN (25 mg/kg) for 24 h additionally induced CYP3A11 expression; however, did not affect the expression of FXR target 
genes (FGF15 and IBABP). The data were normalized to the expression levels of mouse U36B4. The data are presented as the mean ± standard deviation. 
n=3. *P<0.05, **P<0.01, ***P<0.001 vs. respective vehicle. FGF15, fibroblast growth factor 15; Dex, dexamethasone; GR, glucocorticoid receptor; CYP3A11, 
cytochrome P450, family 3, subfamily a, polypeptide 11; FXR, farnesoid X receptor; SHP, small heterodimer partner; IBABP, ileum bile acid binding protein; 
PXR, pregnane X receptor; PCN, pregnenolone-16-α-carbonitrile.
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As Dex is able to activate PXR and GR, it was addition-
ally determined whether the downregulation of Fgf15 by 
Dex may be attributed to GR activation alone (33,35). It was 
demonstrated that PXR may be activated by higher dosages of 
Dex compared with those typically required by classical GR 
activation (33,36,37). In the present study, although PXR addi-
tionally responded to Dex in the ileum, the activation of PXR 
by PCN had no effect on the Fgf15 expression, demonstrating 
that the suppression of Fgf15 expression was not associated 
with PXR activation. Notably, GR, as a classical, accepted 
receptor of Dex, has the highest expression in the ileum among 
the three anatomical parts of the small intestine. Furthermore, 
ileal GR responded to treatment with Dex; the mRNA expres-
sion levels of two selected GR target genes, GILZ and ASBT 
were significantly upregulated. These results suggested that 
GR activation by Dex may be responsible for the suppression 
of FXR activation, leading to the downregulation of Fgf15 
expression in ileum. However, the hypothesis that anti‑GC 
drugs, including RU486, may induce Fgf15 expression based 
on the preliminary data of the present study requires further 
investigation. This investigation may help to better clarify the 
role of GR in regulating Fgf15 expression in the intestine.
How GR activation by Dex inhibits the transcriptional 
activity of FXR remains to be determined. GR is a classical 
receptor for GCs, and the activation of GR may repress a 
number of pro‑inflammatory genes by interacting with nuclear 
factor-κB (NF-κB) (10). For example, GR activation represses 
TNFα and IL‑6 expression by inhibiting NF‑κB transcrip-
tional activity (10). It has additionally been identified that GR 
may interact with FXR, by recruiting the C‑terminal binding 
domain protein and repressing its activity in the liver (38). 
As GR and FXR are transcriptional factors that exhibit high 
expression levels in ileal cells, it is hypothesized that their 
crosstalk may serve an important role. However, further studies 
are required to provide molecular evidence and determine the 
underlying mechanisms.
In summary, the present results suggested that treatment 
with Dex may downregulate ileal Fgf15 expression, and this 
downregulation is associated with GR‑mediated repression 
of FXR activity. The present results provide insight for a 
better understanding of the mechanism of regulation of Fgf15 
expression and suggest the possible occurrence of adverse 
events resulting from Fgf15/19 suppression associated with 
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